Pipeline

Leveraging the power of Glycobiology

Carbohydrates, commonly known as sugars, are found everywhere in nature and are expressed in all forms of life, from viruses and bacteria to plants, invertebrates, and mammals — including humans. All cells in nature are coated with complex carbohydrates that act as recognition molecules, thus enabling interactions with different cells, other molecules, and pathogens, including cell-to-cell binding, cell activation, differentiation, survival, and migration. Small changes in these molecules or the events they control can lead to the development of diseases, including cancer.

At GlycoMimetics, we apply our extensive understanding of carbohydrate biology (“glycobiology”) to rationally design, develop, and commercialize highly potent, small-molecule therapeutics that selectively target molecular mechanisms known to be centrally involved in the causes and progression of various human diseases such as cancer. We harness our development and commercial expertise to move these wholly-owned drug candidates from research through late-stage clinical development.  Our portfolio of investigational E-selectin antagonists includes uproleselan, which is in phase 3 clinical development for people living with acute myeloid leukemia, and GMI-1687, which is in development for people living with sickle cell disease.